Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC

[1]  T. Choueiri,et al.  Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2022, European urology.

[2]  Kongming Wu,et al.  Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy , 2022, Molecular Cancer.

[3]  Xihong Lin,et al.  Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels , 2022, JAMA oncology.

[4]  Gang Huang,et al.  Molecular Imaging of Renal Cell Carcinoma in Precision Medicine. , 2022, Molecular pharmaceutics.

[5]  P. Russo,et al.  Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. , 2022, European urology.

[6]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[7]  S. Hancock,et al.  Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  C. Blank,et al.  Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment , 2022, European Urology Open Science.

[9]  R. Hannan,et al.  Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. , 2021, European urology oncology.

[10]  N. Kyprianou,et al.  From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma , 2021, Cells.

[11]  D. Enikeev,et al.  Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate? , 2021, Current Urology Reports.

[12]  R. Motzer,et al.  Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma , 2021, Cancer.

[13]  E. Abel,et al.  Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy , 2021, Cancer.

[14]  K. Bensalah,et al.  Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? , 2021, European urology.

[15]  S. Culine,et al.  Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. , 2021, European urology.

[16]  B. Trock,et al.  Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. , 2021, European urology oncology.

[17]  Zhi Chen,et al.  Diagnostic value of circulating cell-free DNA for renal cell carcinoma: a meta-analysis , 2021, Translational cancer research.

[18]  Peipei Wang,et al.  Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy , 2021, Frontiers in Oncology.

[19]  M. Voss,et al.  Novel emerging biomarkers to immunotherapy in kidney cancer , 2021, Therapeutic advances in medical oncology.

[20]  R. Autorino,et al.  Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). , 2020, European urology oncology.

[21]  P. Hegde,et al.  Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. , 2020, Cancer cell.

[22]  A. Verbiest,et al.  Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma , 2020, Scandinavian journal of urology.

[23]  Amber C. Donahue,et al.  Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial , 2020, Nature Medicine.

[24]  E. Abel,et al.  The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma. , 2020, The Urologic clinics of North America.

[25]  C. Wood,et al.  Survival following cytoreductive nephrectomy: a comparison of existing prognostic models , 2020, BJU international.

[26]  C. Wood,et al.  Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. , 2020, Cancer.

[27]  U. Capitanio,et al.  Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. , 2020, European urology.

[28]  F. Saad,et al.  Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. , 2020, European urology focus.

[29]  Y. Lotan,et al.  Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. , 2020, Urologic oncology.

[30]  G. Cerqueira,et al.  Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma , 2020, Journal for ImmunoTherapy of Cancer.

[31]  M. Milowsky,et al.  Advanced renal cell carcinoma , 2020, Current treatment options in oncology.

[32]  D. Bossé,et al.  Evolution in upfront treatment strategies for metastatic RCC , 2020, Nature Reviews Urology.

[33]  K. Bensalah,et al.  Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? , 2020, European urology.

[34]  C. Porta,et al.  Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2019, European urology oncology.

[35]  R. Hannan,et al.  Stereotactic Ablative Radiotherapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. , 2019, International journal of radiation oncology, biology, physics.

[36]  W. Sellers,et al.  Metabolomic adaptations and correlates of survival to immune checkpoint blockade , 2019, Nature Communications.

[37]  J. Brugarolas,et al.  Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. , 2019, Urologic oncology.

[38]  U. Röhrig,et al.  Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond , 2019, Nature Reviews Drug Discovery.

[39]  R.C.E. van Velthoven,et al.  Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial , 2019, JAMA oncology.

[40]  D. Ribatti,et al.  Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma , 2018, Aging.

[41]  R. Hannan,et al.  Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal‐Cell Carcinoma: A Nationwide Cancer Registry Study , 2018, Clinical genitourinary cancer.

[42]  A. Broeks,et al.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.

[43]  S. Boorjian,et al.  Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma , 2018, The Journal of urology.

[44]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[45]  G. Mayhew,et al.  Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal , 2018, Cell.

[46]  P. A. Futreal,et al.  Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal , 2018, Cell.

[47]  A. Matakidou,et al.  Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting , 2018, World Journal of Urology.

[48]  C. Niu,et al.  Gamma-delta (γδ) T cells: friend or foe in cancer development? , 2018, Journal of Translational Medicine.

[49]  J. Zapata-Copete,et al.  Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis , 2017, Investigative and clinical urology.

[50]  A. Briganti,et al.  Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. , 2017, European urology focus.

[51]  J. Gore,et al.  Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort. , 2017, Urology.

[52]  David P. Smith,et al.  Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival , 2017, Cancer medicine.

[53]  R. Motzer,et al.  Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. , 2017, Urologic oncology.

[54]  P. Ditonno,et al.  Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. , 2017, Urologic oncology.

[55]  Simon P. Kim,et al.  Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[56]  T. Choueiri,et al.  Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials , 2017, Clinical genitourinary cancer.

[57]  Yang Xia,et al.  Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway , 2017, Oncotarget.

[58]  S. Barni,et al.  Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. , 2016, Clinical genitourinary cancer.

[59]  Ludmila V. Danilova,et al.  Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[60]  P. Gibbs,et al.  Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‐to‐lymphocyte ratio in patients with metastatic renal cell carcinoma , 2016, Internal medicine journal.

[61]  G. Oades,et al.  Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. , 2016, JAMA oncology.

[62]  L. Kiemeney,et al.  Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry. , 2016, Urology.

[63]  A. Korman,et al.  Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype. , 2017, Cellular immunology.

[64]  P. Tamboli,et al.  Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. , 2016, European urology.

[65]  C. Blank,et al.  Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy , 2016, World Journal of Urology.

[66]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[67]  S. Nakada,et al.  Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. , 2015, The Journal of urology.

[68]  K. Bensalah,et al.  Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. , 2015, Urologic oncology.

[69]  R. Rong,et al.  Skewed T-helper (Th)1/2- and Th17/T regulatory-cell balances in patients with renal cell carcinoma , 2014, Molecular medicine reports.

[70]  E. Noessner,et al.  NK‐cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention , 2014, International journal of cancer.

[71]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[72]  A. Kibel,et al.  Cytoreductive nephrectomy in patients with metastatic non‐clear‐cell renal cell carcinoma (RCC) , 2014, BJU international.

[73]  T. Choueiri,et al.  Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria , 2013, Cancer.

[74]  V. Margulis,et al.  Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. , 2013, European urology.

[75]  A. Frey,et al.  Myeloid-Derived Suppressor Cells and anti-tumor T cells: a complex relationship , 2012, Immunological investigations.

[76]  P. Tamboli,et al.  Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. , 2011, European urology.

[77]  V. Margulis,et al.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? , 2010, Cancer.

[78]  J. Patard,et al.  Conditional survival predictions after nephrectomy for renal cell carcinoma. , 2009, The Journal of urology.

[79]  C. Wood,et al.  Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy , 2009, Nature Reviews Urology.

[80]  J. Patard,et al.  Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. , 2009, Urology.

[81]  B. Rini,et al.  The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. , 2007, The Journal of urology.

[82]  J. Cheville,et al.  A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. , 2005, The Journal of urology.

[83]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[84]  S. Campbell,et al.  Nephrectomy in metastatic renal cell carcinoma , 2003, Current treatment options in oncology.

[85]  G. Köhler,et al.  Pro-Inflammatory and T Cell Inhibitory Cytokines Are Secreted at High Levels in Tumor Cell Cultures of Human Renal Cell Carcinoma , 1999, European Urology.

[86]  K. Bensalah,et al.  Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. , 2019, European urology.

[87]  P. Tamboli,et al.  Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. , 2011, European urology.

[88]  Dae-Ho Lee,et al.  The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. , 2011, The Journal of urology.

[89]  T. Choueiri,et al.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. , 2011, The Journal of urology.